{
  "abstract": "Background: Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has demonstrated renoprotective effects in randomized controlled trials. However, real-world evidence, particularly in heterogeneous and non-diabetic chronic kidney disease (CKD) populations, remains limited.\n\nMethods: This was a single-center, retrospective, real-world cohort study of adults with non-diabetic CKD who initiated finerenone. Longitudinal changes in urinary albumin-to-creatinine ratio (UACR) and 24 h urinary protein (24 hUP) were analyzed using covariate-adjusted gamma-log generalized estimating equation (GEE) models with an autoregressive correlation structure of order 1 [AR(1)] and robust standard errors, whereas eGFR trajectories were evaluated using a covariate-adjusted segmented linear mixed-effects model. The UACR and 24 hUP models were adjusted for age, sex, RASi use, SGLT−2i use, and immunosuppressant use; the eGFR model additionally included baseline UACR category. Subgroup heterogeneity was assessed using interaction tests, with Benjamini–Hochberg false discovery rate correction.\n\nResults: Among 121 patients, finerenone initiation was associated with reductions in UACR and 24 hUP. The adjusted changes in UACR were −48.6% at Month 12 (95% CI, −60.1% to −33.8%; P < 0.001) and −35.4% at Month 24 (95% CI, −63.4% to 14.0%; P = 0.132). The corresponding adjusted changes in 24 hUP were −34.5% (95% CI, −47.3% to −18.6%; P < 0.001) and −34.9% (95% CI, −56.6% to −2.4%; P = 0.038), respectively. The annualized eGFR slope attenuated from −6.51 mL/min/1.73 m2/year (95% CI, −9.70 to −3.31) before finerenone initiation to −1.44 mL/min/1.73 m2/year (95% CI, −3.52 to 0.64) after initiation, corresponding to a slope improvement of 5.07 mL/min/1.73 m2/year (95% CI, 1.86 to 8.27; P = 0.002). No serious adverse events were documented during follow-up; hyperkalemia occurred in 4.96% of patients, and neither hyperkalemia nor hypotension prompted treatment discontinuation.\n\nConclusion: In this real-world cohort, finerenone was associated with reductions in UACR and 24 hUP and attenuation of eGFR decline, with infrequent observed hyperkalemia and hypotension during the available follow-up.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Nephrology (Fujian Provincial Clinical Research Center for Glomerular Nephritis), The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University , ,",
    "The School of Clinical Medicine, Fujian Medical University , ,"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xuejuan Sun"
    },
    {
      "affs": [
        0
      ],
      "name": "Juan Pei"
    },
    {
      "affs": [
        0
      ],
      "name": "Xing Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhi Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Lijing Yao"
    },
    {
      "affs": [
        0
      ],
      "name": "Peijin Bai"
    },
    {
      "affs": [
        1
      ],
      "name": "Zhiwen Yan"
    },
    {
      "affs": [
        0
      ],
      "name": "Yinan Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Leping Shao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9rpsvjmphqsjx.bib",
  "cited_by": 0,
  "doi": "10.3389/fmed.2026.1959259",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724480/?tool=EBI",
  "id": "9rpsvjmphqsjx",
  "issns": [
    "2296-858X"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13724480",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2727|Chronic Kidney Disease and Diabetes"
    ]
  ],
  "openalex": "W7222924528",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724480/pdf/?tool=EBI",
  "pmcid": "PMC13724480",
  "pmid": "42973695",
  "published": "2026-10-19",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/9rpsvjmphqsjx.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T15:20:51Z",
      "native_id": "PMC:PMC13724480",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13724480"
    },
    {
      "first_seen": "2026-11-04T12:23:02Z",
      "native_id": "PMC13724480",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fmed.2026.1959259"
    },
    {
      "first_seen": "2026-11-04T15:20:48Z",
      "native_id": "MED:42973695",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42973695"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2727|Chronic Kidney Disease and Diabetes",
      "subfield": "general"
    }
  ],
  "title": "Longitudinal kidney outcomes and safety after finerenone initiation in patients with non-diabetic chronic kidney disease: a single-center retrospective cohort study",
  "title_text": "Longitudinal kidney outcomes and safety after finerenone initiation in patients with non-diabetic chronic kidney disease: a single-center retrospective cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:20:56Z",
  "url": "https://research.draconitic.com/paper/9rpsvjmphqsjx",
  "venue": "Frontiers in medicine",
  "versions": []
}